Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

Kate D. Lynch(Royal Adelaide Hospital), Cynthia Levy(University of Miami), Manon de Krijger(Amsterdam University Medical Centers), Aldo J. Montaño‐Loza(University of Alberta), Nicola Perin(University of Padua), Lei Yu(University of Alberta), L.M. Daretti(Azienda Ospedaliero-Universitaria delle Marche), David N. Assis(Yale University), Annika Bergquist(Karolinska University Hospital), Derek Estes(University of Miami), Christoph Schramm(European Association for the Study of Diabetes), Gideon M. Hirschfield(University Health Network), Annemarie C. de Vries(Erasmus MC), Christopher L. Bowlus(University of California, Davis), Henriette Ytting(University of Copenhagen), Roger W. Chapman, Benedetta Terziroli Beretta‐Piccoli(Ente Ospedaliero Cantonale), Jennifer K. Rogers(University of Oxford), Marco Marzioni(Marche Polytechnic University), James L. Boyer(Celldex Therapeutics (United States)), Annarosa Floreani(University of Padua), Cyriel Y. Ponsioen(Amsterdam UMC Location University of Amsterdam), Daniel S. Pratt(University of Colorado Denver), Charlotte Hedin(Karolinska University Hospital), Palak Trivedi(University Hospitals Birmingham NHS Foundation Trust), Satish Keshav(John Radcliffe Hospital), Andrew L. Mason(Ochsner Medical Center), Hanns–Ulrich Marschall(University of Padua), Kidist Yimam(California Pacific Medical Center), Andreas E. Kremer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Michael Trauner(Medical University of Vienna), C. Janneke van der Woude(Radboud University Nijmegen), Emina Hallibasic(Medical University of Vienna), Chung Heng Liu(University of California, Davis), Marcel Vetter(Martin Luther University Halle-Wittenberg)
Clinical Gastroenterology and Hepatology
May 14, 2019
Cited by 104


Related Papers